Related Experiment Video
Updated: Jun 28, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhi-Feng Zou1,2, Lei Yang2,3, Hui-Jun Nie3
1School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
Abstract:
Proteolysis targeting chimeras (PROTACs) have emerged as revolutionary anticancer therapeutics that degrade disease-causing proteins. However, the anticancer performance of PROTACs is often impaired by their insufficient bioavailability, unsatisfactory tumor specificity and ability to induce acquired drug resistance. Herein, we propose a polymer-conjugated PROTAC prodrug platform for the tumor-targeted delivery of the most prevalent von Hippel-Lindau (VHL)- and cereblon (CRBN)-based PROTACs, as well as for the precise codelivery of a degrader and conventional small-molecule drugs. The self-assembling PROTAC prodrug nanoparticles (NPs) can specifically target and be activated inside tumor cells to release the free PROTAC for precise protein degradation. The PROTAC prodrug NPs caused more efficient regression of MDA-MB-231 breast tumors in a mouse model by degrading bromodomain-containing protein 4 (BRD4) or cyclin-dependent kinase 9 (CDK9) with decreased systemic toxicity. In addition, we demonstrated that the PROTAC prodrug NPs can serve as a versatile platform for the codelivery of a PROTAC and chemotherapeutics for enhanced anticancer efficiency and combination benefits. This study paves the way for utilizing tumor-targeted protein degradation for precise anticancer therapy and the effective combination treatment of complex diseases.
Insights
This study introduces a polymer-conjugated PROTAC prodrug platform for targeted cancer therapy. This innovative nanoparticle system enhances drug delivery, improves tumor specificity, and offers combination treatment benefits for complex diseases.
Area of Science:
- Biochemistry
- Nanotechnology
- Oncology
Background:
- Proteolysis targeting chimeras (PROTACs) are promising anticancer agents that degrade disease-causing proteins.
- Current PROTAC limitations include poor bioavailability, low tumor specificity, and acquired drug resistance.
Purpose of the Study:
- To develop a polymer-conjugated PROTAC prodrug platform for tumor-targeted delivery.
- To enable precise co-delivery of PROTACs and conventional chemotherapeutics.
Main Methods:
- Self-assembling nanoparticles (NPs) were engineered to carry PROTAC prodrugs.
- Targeted delivery and activation within tumor cells were achieved.
- In vivo studies utilized a mouse model of MDA-MB-231 breast tumors.
Main Results:
- PROTAC prodrug NPs demonstrated enhanced tumor regression by degrading BRD4 or CDK9.
- Systemic toxicity was reduced compared to conventional PROTACs.
- The platform facilitated effective co-delivery of PROTACs and chemotherapeutics.
Conclusions:
- The developed PROTAC prodrug NP platform offers improved tumor targeting and bioavailability.
- This versatile platform enhances anticancer efficacy through precise protein degradation and combination therapy.
- This approach represents a significant advancement in targeted anticancer therapy and complex disease treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...